The ability of the intercellular AGR2 to enhance drug resistance is likely to be consequential to its ability to regulate the ERAD pathway, while expression of eAGR2 is likely to contribute to the resilience of cancer cells that are surviving in an inflammatory microenvironment. The gene discussed is AGR2; the disease is cancer.